|
May 11
|
Aadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To Know
|
|
May 10
|
Analysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue Forecasts
|
|
May 9
|
Aadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)
|
|
May 8
|
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
|
|
May 1
|
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
|
|
Apr 9
|
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
|
|
Mar 17
|
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
|
|
Mar 14
|
Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)
|
|
Mar 13
|
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
|
|
Mar 6
|
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
|
|
Mar 5
|
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Jan 19
|
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
|
|
Nov 8
|
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
|
|
Nov 6
|
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
|